SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

[Tinnitus Talk]

Tinnitus Talk submitted a new resource:

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss (version 1.0) - To determine the safety and efficacy of SPI-1005 to prevent and treat chemotherapy-induced HL.

Chemotherapy treatment with the platinum containing chemotherapies (cisplatin, carboplatin) are well noted and studied for their ability to cause a side effect of hearing loss, also termed ototoxicity. It is the objective of this study to determine the safety and efficacy of SPI-1005 at three dose levels when delivered orally twice daily for 3 days, during each cycle of cisplatin chemotherapy for head and neck or non-small cell lung cancer patients to prevent and treat chemotherapy induced...

Read more about this resource...

 

[Frédéric]

https://clinicaltrials.gov/ct2/show/NCT01451853
Status: still not yet recruiting. Estimated study completion date: September 23, 2019